Sun Pharmaceutical Industries on Friday said it has launched skin cancer drug Unloxcyt in the US market.

Unloxcyt (cosibelimab-ipdl) is now available in the US for healthcare professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (llaCSCC) who are not candidates for curative surgery, the Mumbai-based drug major said in a statement.